Double punch for lymphoma: stem cell transplant plus CAR-T therapy
NCT ID NCT06365671
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether giving a special immune cell treatment (CAR-T) right after a stem cell transplant can help people with aggressive B-cell lymphoma that has not responded to standard treatments. The trial will enroll 16 people and measure how many achieve complete remission within 3 months. The approach aims to wipe out remaining cancer cells after the transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- relmacabtagene autoleucel (relma-cel), a type of CAR-T cell therapy
- What this could lead to
- If it works, this could offer a new treatment option for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy.
- What could go wrong
- This is a small, early-phase trial with only 16 people, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?